Proactiveinvestors Australia

Benitec Biopharma www.benitec.com/

Benitec Biopharma (ASX: BLT) is investigating long term gene silencing using DNA-directed RNA interference (ddRNAi) for human therapeutics. The company’s primary therapeutic program focuses on human immunodeficiency virus (HIV). Its other projects are in the area of infectious diseases and cancer.

Pdf

Benitec endorsement of Pain Program from US and European clinical pain specialists

Tuesday, September 20, 2011 by John Phillips

Benitec endorsement of Pain Program from US and European clinical pain specialists

Benitec's (ASX: BLT) company strategy is focused on developing new therapies for life-threatening diseases based on long-term silencing of genes.

In an update to the market, Benitec has highlighted that the company has received a strong endorsement of the Pain Program from U.S. and European clinical pain specialists.

Benitec is currently attempting to fast track the pre-clinical, clinical and commercial development of the company's lead program, which is a novel gene silencing therapeutic for intractable cancer-associated neuropathic pain.

In addition, Benitec has appointed U.S. based Ground Zero Pharmaceuticals as the CRO to advance the pain program into clinical testing under a USFDA-approved protocol.

Peter French, chief executive officer for Benitec, commented "These findings validate our pain program directly from the pain clinicians themselves.

"It reinforces our focus on the pain program, and provide the impetus for Benitec to mobilize additional resources to the program and to progress to the next stage of Benitec's commercial outreach for this program in the U.S. and Europe with Campbell Alliance."

 

Sign up to Proactive Investors

Andrew McCrea's Research Reports
Sign up to Andrew McCrea's Research Reports and Receive Latest Research & Flash Trades
Receive Proactive Investors Newsletter, Investor Forum Invites
Receive Proactive Investors Newsletter, Event Invites, Special Stock Notifications

Comments from Proactive Investors readers

  • Fill in your details below:
Verification Code
Andrew McCrea is Sub Authorised Representative (SAR: 291331) of Proactive Investors Australia Pty Ltd
(ABN: 19 132 787 654) which is a Corporate Auhorised Representative (CAR: 413802) of RM Capital
Pty Ltd (AFSL: 221938).

Copyright © proactiveinvestors.com.au, 2012. All Rights Reserved